Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ruhr University of Bochum | OTHER |
| Hôpital de Braine-l'Alleud | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The prilocaine is a very common local anesthetic that has the disadvantage of being metabolized to o-toluidine, a human carcinogen.
Hyperbaric 2% prilocaine (HP), recently developped, is increasingly used for spinal anesthesia in ambulatory surgery. But the formation of carcinogenic metabolites induced by the hyperbaric prilocaine is not yet known. The aim of this study is to investigate whether the intrathecal administration of 50 mg hyperbaric prilocaine induces also the formation of carcinogenic complexes such as urinary o-toluidine and hemoglobin adducts from o-toluidine in blood.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Hemoglobin adducts from o-toluidine in blood | Hemoglobin adducts from o-toluidine in blood is measured before surgery (at admission) | Time 0 (before surgery) |
| Hemoglobin adducts from o-toluidine in blood | Hemoglobin adducts from o-toluidine in blood is measured at 24 hours after intrathecal prilocaine injection | Time 24 hours after intrathecal prilocaine injection |
| Urinary o-toluidine | Urinary o-toluidine is measured before surgery (at admission) | Time 0 (before surgery) |
| Urinary o-toluidine | Urinary o-toluidine is measured at 6 hours after intrathecal prilocaine injection | Time 6 hours after intrathecal prilocaine injection |
| Urinary o-toluidine | Urinary o-toluidine is measured at 12 hours after intrathecal prilocaine injection | Time 12 hours after intrathecal prilocaine injection |
| Urinary o-toluidine | Urinary o-toluidine is measured at 24 hours after intrathecal prilocaine injection | Time 24 hours after intrathecal prilocaine injection |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patient scheduled for an ambulatory surgery
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emmanuel Guntz, MD | Université Libre de Bruxelles (ULB), Braine-l'Alleud Hospital | Study Director |
| Panayota Kapessidou, MD,PhD | University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Braine-l'Alleud Hospital | Braine-l'Alleud | 1420 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17129655 | Background | Gaber K, Harreus UA, Matthias C, Kleinsasser NH, Richter E. Hemoglobin adducts of the human bladder carcinogen o-toluidine after treatment with the local anesthetic prilocaine. Toxicology. 2007 Jan 5;229(1-2):157-64. doi: 10.1016/j.tox.2006.10.012. Epub 2006 Oct 29. | |
| 20529983 | Background | Camponovo C, Fanelli A, Ghisi D, Cristina D, Fanelli G. A prospective, double-blinded, randomized, clinical trial comparing the efficacy of 40 mg and 60 mg hyperbaric 2% prilocaine versus 60 mg plain 2% prilocaine for intrathecal anesthesia in ambulatory surgery. Anesth Analg. 2010 Aug;111(2):568-72. doi: 10.1213/ANE.0b013e3181e30bb8. Epub 2010 Jun 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood (2 samples) and Urine (4 samples)
| 24906303 | Background | Guntz E, Latrech B, Tsiberidis C, Gouwy J, Kapessidou Y. ED50 and ED90 of intrathecal hyperbaric 2% prilocaine in ambulatory knee arthroscopy. Can J Anaesth. 2014 Sep;61(9):801-7. doi: 10.1007/s12630-014-0189-7. Epub 2014 Jun 7. |
| 23199005 | Background | Gebhardt V, Herold A, Weiss C, Samakas A, Schmittner MD. Dosage finding for low-dose spinal anaesthesia using hyperbaric prilocaine in patients undergoing perianal outpatient surgery. Acta Anaesthesiol Scand. 2013 Feb;57(2):249-56. doi: 10.1111/aas.12031. Epub 2012 Nov 30. |
| 21117897 | Background | Bohm F, Schmid D, Denzinger S, Wieland WF, Richter E. DNA adducts of ortho-toluidine in human bladder. Biomarkers. 2011 Mar;16(2):120-8. doi: 10.3109/1354750X.2010.534556. Epub 2010 Nov 30. |
| 33475793 | Derived | Guntz E, Carini A, Koslitz S, Bruning T, Kapessidou P, Weiss T. Quantification of systemic o-toluidine after intrathecal administration of hyperbaric prilocaine in humans: a prospective cohort study. Arch Toxicol. 2021 Mar;95(3):925-934. doi: 10.1007/s00204-021-02973-w. Epub 2021 Jan 21. |